What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed as Mounjaro (type 2 diabetes) and Zepbound (weight management). Unlike semaglutide which targets only GLP-1, tirzepatide also activates GIP receptors, creating a dual mechanism that may offer enhanced metabolic benefits. In the SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of body weight over 72 weeks.
How to Reconstitute Tirzepatide
Reconstitute lyophilized tirzepatide with bacteriostatic water using sterile technique. Direct the stream of water against the glass wall, not the powder cake. Swirl gently — do not shake. The solution should be completely clear before use.
BAC Water by Vial Size
- 5 mg → 2 mL BAC water (2.5 mg/mL)
- 10 mg → 2 mL BAC water (5 mg/mL)
- 15 mg → 3 mL BAC water (5 mg/mL)
- 30 mg → 3 mL BAC water (10 mg/mL)
Titration Schedule
Tirzepatide follows a gradual escalation similar to semaglutide. Each dose level should be maintained for at least 4 weeks before increasing. Some users find they reach effective weight management at lower doses (7.5–10 mg) and do not need to escalate to 15 mg.
- Weeks 1–4: 2.5 mg weekly
- Weeks 5–8: 5 mg weekly
- Weeks 9–12: 7.5 mg weekly
- Weeks 13–16: 10 mg weekly
- Weeks 17–20: 12.5 mg weekly
- Weeks 21+: 15 mg weekly (max maintenance)
Tirzepatide vs Semaglutide
Head-to-head trials (SURPASS-2) showed tirzepatide produced greater weight loss than semaglutide at equivalent dose escalation timelines. However, tirzepatide is newer and has less long-term safety data. Both require gradual titration and share similar GI side effects. Choice between them often depends on individual response and prescriber recommendation.
Storage
Unreconstituted: freezer at −20°C. Reconstituted: fridge at 2–8°C, use within 28 days. Protect from light and temperature fluctuations.
Educational purposes only. Tirzepatide is a prescription medication. Consult a healthcare provider.